Clinical trials: Asthma Management
- Condition Asthma Management
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Asthma
Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma
To compare the efficacy and safety of the fixed combination asthma drug Flutiform HFA MDI with its two components administered alone, fluticasone propionate and formoterol fumarate, in adult and adolescent patients with mild to…
- Trial name
- NCT00394199
- Testing
- Fluticasone propionate/Formoterol Fumarate 100/10, Fluticasone propionate 100, Formoterol fumarate 10
- Where
- 41 sites in United States, Canada
- Volunteers
- 357 people
- Sponsor
- SkyePharma AG
Asthma
Investigation of Intravenous (IV) Administration of an Approved Drug (MK-0476, Montelukast Sodium) for Acute Asthma (MK-0476-288)
The purpose of this study is to evaluate improved results of treatment for patients entering an emergency department with asthma attacks when given an investigational IV administration of an approved drug (MK-0476, montelukast…
- Trial name
- NCT00092989
- Testing
- montelukast sodium
- Volunteers
- 650 people
- Sponsor
- Organon and Co
Bronchial Asthma
Two Doses of the Intravenous Magnesium Sulfate Versus the Standard Single Dose ,With/ Without the Nebulized Budesonide For the Management of the Severe Asthma Exacerbation in the Emergency Room; A Randomized Controlled Trial.
Many studies have investigated the efficacy and safety of Intravenous magnesium sulfate and inhaled steroids in addition to the standard treatment for patients with severe asthma attacks.
- Trial name
- NCT02455687
- Testing
- Hi-dose iv MgSO4, Nebulized budesonide, Std-dose iv MgSO4
- Where
- Qatar
- Volunteers
- 240 people
- Sponsor
- Hamad Medical Corporation
Asthma
Management of Asthma Patients Guided by Exhaled Nitric Oxide (eNO)
This study is designed to show that pharmacotherapy guided by eNO and clinical standard of care produces a superior outcome to trial-based therapy guided by clinical standard of care alone.
- Trial name
- Outcomes (NCT00739219)
- Testing
- Apieron Insight eNO monitor
- Where
- 12 sites in United States
- Volunteers
- 260 people
- Sponsor
- Apieron
Asthma
Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
This study aimed to determine the efficacy and safety of QAW039 150 mg and QAW039 450 mg, compared with placebo, when added to GINA (Global Initiative for Asthma) steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2016)…
- Trial name
- NCT02555683
- Testing
- QAW039
- Where
- 234 sites in United States, Argentina and 25 more
- Volunteers
- 894 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
FLOVENT Hydrofluoroalkane (HFA) In 6-12 Month Old Subjects
The purpose of this study is to address an Food Drug and Administration (FDA) request to provide safety data in pre-asthmatic patients, ages 6 months to <12 months, following administration of fluticasone propionate HFA.
- Trial name
- NCT00370097
- Testing
- FLOVENT (fluticasone propionate) HFA
- Where
- 7 sites in United States
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Asthma
Study of Mepolizumab Autoinjector in Asthmatics
This study is aimed to assess the correct real-world use of an autoinjector for the repeat self-administration of mepolizumab SC, so to improve subject / physician convenience and to enable repeat dose self injection themselves…
- Trial name
- NCT03099096
- Testing
- Mepolizumab
- Where
- 38 sites in United States, Australia and 5 more
- Volunteers
- 159 people
- Sponsor
- GlaxoSmithKline
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Asthma
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
This study aimed to determine the efficacy and safety of QAW039 and QAW039 450 mg compared to placebo, when added to GINA (Global Initiative for Asthma) steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2016) in the…
- Trial name
- NCT02563067
- Testing
- QAW039
- Where
- 163 sites in United States, Argentina and 17 more
- Volunteers
- 877 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma
The purpose of this study is to compare the efficacy and safety of the fixed combination asthma drug FlutiForm HFA MDI with its two components administered alone, fluticasone propionate and formoterol fumarate, and with placebo…
- Trial name
- NCT00393991
- Testing
- Fluticasone propionate/formoterol fumarate 100/10, Fluticasone propionate 100, Formoterol fumarate 10
- Where
- 57 sites in United States, Canada
- Volunteers
- 475 people
- Sponsor
- SkyePharma AG
Asthma
Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment
This study was a 2-treatment period, randomized, multicenter parallel-group study. The overall purpose of this study was to provide long- term safety data for fevipiprant (QAW039) (Dose 1 and Dose 2), compared with placebo, when…
- Trial name
- NCT03052517
- Testing
- QAW039 150 mg, QAW039 450 mg
- Where
- 347 sites in United States, Argentina and 40 more
- Volunteers
- 2,538 people
- Sponsor
- Novartis Pharmaceuticals
Patients With Asthma-COPD Overlap Syndrome (ACOS)
Non-interventional Study of COPD Patients With Asthma Overlap Syndrome in Viet Nam and Taiwan
The purpose of this study to determine the proportion and clinical characteristics of COPD patients with asthma symptoms (ACOS) and describe current practices in diagnosis and management in Viet Nam and Taiwan.
- Trial name
- NCT02878252
- Where
- 5 sites in Taiwan, Vietnam
- Volunteers
- 350 people
- Sponsor
- AstraZeneca
Asthma
The Clinical Effect of MK0476 With Concomitant Administration of and Removal of Inhaled Beclomethasone in Asthmatic Patients (0476-029)
This study will investigate the additive effect of montelukast (MK0476) taken along with inhaled beclomethasone versus inhaled beclomethasone alone.
- Trial name
- NCT00911547
- Testing
- montelukast sodium, beclomethasone
- Volunteers
- 642 people
- Sponsor
- Organon and Co
Asthma in Children
AmbuLatory Pediatric Asthma CAre
The ALPACA study has a prospective randomized control interventional design, including a follow-up period to evaluate follow-up effects. The study is divided into two phases of 3 months using eHealth and observational monitoring.
- Trial name
- NCT05517096
- Testing
- E-Health
- Where
- Netherlands
- Volunteers
- healthy volunteers welcome
- Sponsor
- Philips Clinical & Medical Affairs Global
Asthma
Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma
ARS-1 is being developed for patients as a needleless alternative route of epinephrine administration for the management of refractory asthma symptoms.
- Trial name
- NCT05363670
- Testing
- ARS-1 1 mg, Albuterol MDI, ARS-1 2mg
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- ARS Pharmaceuticals, Inc.
Asthma
Online Asthma Self-Management for Children Aged 5-10 and Their Parents
The potential benefits of this research to public health include improved understanding of cultural factors in pediatric asthma self-management, improved self-management skills for children, and better asthma management skills…
- Trial name
- ChildAsthma (NCT02602392)
- Testing
- Lungtropolis, Asthma educational booklet
- Where
- United States
- Volunteers
- 622 people, healthy volunteers welcome
- Sponsor
- Oregon Center for Applied Science, Inc.
Asthma
Study to Evaluate the Impact of FeNO Assessments on Asthma Management Decisions in Subject 7 to 60 Years of Age
Objective: To evaluate the impact of FeNO assessments on asthma treatment decisions. Secondary objectives: Evaluate the ability of physicians to correctly assess airway inflammation using standard clinical assessment tools (i.e.…
- Trial name
- NCT01729247
- Testing
- NIOX MINO® Instrument (09-1100)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Aerocrine AB
Asthma in Children
Probiotics in Paediatric Asthma Management
Randomized controlled double-blind trial in a child population with allergic asthma and recurring wheezing, undergoing probiotic treatment with Bifiasthm with the aim of assessing the reduction in asthma attacks.
- Trial name
- ProPAM (NCT04289441)
- Testing
- Bifiasthm
- Where
- Italy
- Volunteers
- 46 people
- Sponsor
- Probiotical S.p.A.
Asthma
Pediatric Asthma Study Using Stepwise Treatment With Two Food And Drug Administration Approved Asthma Medications
This study was designed to evaluate if, in children with asthma, a stepwise treatment (five levels varying from once daily fluticasone propionate 100mcg until twice daily a fixed combination of salmeterol and fluticasone…
- Trial name
- NCT00158834
- Testing
- Salmeterol/Fluticasone propionate combination product, Fluticasone propionate
- Where
- 16 sites in Netherlands
- Volunteers
- 200 people
- Sponsor
- GlaxoSmithKline
Asthma
Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma
A randomized, multicenter, double-blind, placebo- controlled parallel-group study to determine the efficacy and safety of QAW039, compared with placebo, when added to standard-of-care (SoC) asthma therapy in adult and adolescent…
- Trial name
- NCT03215758
- Testing
- QAW039
- Where
- 110 sites in United States, Argentina and 8 more
- Volunteers
- 675 people
- Sponsor
- Novartis Pharmaceuticals